Company intelligence / Profile preview

Rivulet

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Rivulet is a preclinical-stage biotechnology company focused on developing next-generation ion channel modulators for the treatment of neurological disorders. The company's primary focus is on the KCNQ (Kv7) family of potassium channels, which play a critical role in regulating neuronal excitability. By designing highly selective small molecules, Rivulet aims to address significant unmet needs in conditions such as developmental and epileptic encephalopathy (DEE) and chronic pain. The company is led by an experienced team with a track record in neuroscience drug discovery and ion channel pharmacology.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Rivulet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rivulet.

Explore the full profile